Actelion Ltd.
is a leading
biopharmaceutical
company focused
on the discovery,
development
and commercialization
of innovative drugs
for diseases
with significant
unmet medical needs.

Actelion's Annual General Meeting of Shareholder 2017

Shareholders approve demerger of Actelion’s drug discovery and early clinical pipeline to form
new company Idorsia

Shareholders approve demerger of Actelion’s drug discovery and early clinical pipeline to form
new company Idorsia

Global Actelion

Hotspot of possibilities

Actelion has subsidiaries in over 30 countries, covering all major pharmaceutical markets worldwide

Hotspot of possibilities

Actelion has subsidiaries in over 30 countries, covering all major pharmaceutical markets worldwide

Shareprice

ATLN SIX Swiss Exchange

Shareprice
At 17:30:15 CET 28/04/2017
CHF 265,60Up Down image
-8,10 (-2,96%)